Prospective evaluation of 18F-NaF and 18F-FDG PET/CT in detection of occult metastatic disease in biochemical recurrence of prostate cancer - Wikidata - wikimedia - TriplyDB

Prospective evaluation of 18F-NaF and 18F-FDG PET/CT in detection of occult metastatic disease in biochemical recurrence of prostate cancer

Prospective evaluation of 18F-NaF and 18F-FDG PET/CT in detection of occult metastatic disease in biochemical recurrence of prostate cancer

http://www.wikidata.org/entity/Q36033412

about

Update on positron emission tomography for imaging of prostate cancer Updates of prostate cancer staging: Prostate-specific membrane antigen Positron emission tomography in imaging evaluation of staging, restaging, treatment response, and prognosis in prostate cancer.Update on advances in molecular PET in urological oncology Prostate-Specific Antigen and Prostate-Specific Antigen Kinetics in Predicting 18F-Sodium Fluoride Positron Emission Tomography-Computed Tomography Positivity for First Bone Metastases in Patients with Biochemical Recurrence after Radical Prostatect Imaging evaluation of prostate cancer with 18F-fluorodeoxyglucose PET/CT: utility and limitations Comparative performance of PET tracers in biochemical recurrence of prostate cancer: a critical analysis of literature.Sodium 18F-fluoride PET/CT of bone, joint, and other disorders.Oligometastases in prostate cancer: restaging stage IV cancers and new radiotherapy options.(18)F-FDG-PET/CT and (18)F-NaF-PET/CT in men with castrate-resistant prostate cancer.Molecular imaging of prostate cancer: PET radiotracers.The role of 18F-NaF PET/CT in metastatic bone disease PET/CT in prostate cancer: non-choline radiopharmaceuticals.(18)F-fluorodeoxyglucose PET/CT for detection of disease in patients with prostate-specific antigen relapse following radical treatment of a local-stage prostate cancer.Radium-223-Dichloride in Castration Resistant Metastatic Prostate Cancer-Preliminary Results of the Response Evaluation Using F-18-Fluoride PET/CT PET of Glucose Metabolism and Cellular Proliferation in Prostate Cancer.Bone metastases in hepatocellular carcinoma: an emerging issue.A paradigm shift from anatomic to functional and molecular imaging in the detection of recurrent prostate cancer.Circulating tumour cells-monitoring treatment response in prostate cancer.Tackling non-metastatic castration-resistant prostate cancer: special considerations in treatment.A Pilot Trial Evaluating Zoledronic Acid Induced Changes in [(18)F]FMAU-Positron Emission Tomography Imaging of Bone Metastases in Prostate Cancer.PET imaging of recurrent and metastatic prostate cancer with novel tracers.Is There Use for FDG-PET in Prostate Cancer?Comparison of NaF and FDG PET/CT for assessment of treatment response in castration-resistant prostate cancers with osseous metastases.When to perform positron emission tomography/computed tomography or radionuclide bone scan in patients with recently diagnosed prostate cancer.Optimizing an 18F-NaF and 18F-FDG cocktail for PET assessment of metastatic castration-resistant prostate cancer.Potential of asphericity as a novel diagnostic parameter in the evaluation of patients with 68Ga-PSMA-HBED-CC PET-positive prostate cancer lesions.Combined 18F-fluoride and 18F-FDG PET/CT: a response based on actual data from prospective studies.Care of cancer patients with liver and bone metastases - the place of pharmaceutical care in a balanced plan, focused on the patient's needs and goals.Surrogate end points in early prostate cancer clinical states: ready for implementation?Advances in prostate-specific membrane antigen PET of prostate cancer.The use of PET/CT in prostate cancer.Prostate cancer post-treatment follow-up and recurrence evaluation.Prostate cancer: Intermediate efficacy end points to assess modern therapies.Trigger pSA predicting recurrence from positive choline PET/CT with prostate cancer after initial treatment.Role of PET imaging for biochemical recurrence following primary treatment for prostate cancer

P2860

Q27026828-0F5489B1-DCC4-4370-A24A-29F6924F6A32 Q28079444-D567B3D2-FCC7-43A1-9249-4D351DDA8F9A Q33625371-C85278F8-682F-4A08-A017-5A09B95929F0 Q33625389-177619DC-ECF1-4718-90BD-0AF62C2CFCB5 Q33767672-07E90079-185E-450E-A84A-07CE42528C07 Q34035683-8F8ECCE2-E220-475D-A2A1-8AA6D3A48ED9 Q34228828-A6D2B2FB-148D-4AD9-88D0-66410736B5C6 Q34642993-A32560E2-884C-40A8-8D32-88021B891DF9 Q34748629-F99BCB4A-D5AB-4E55-BA9F-24AE727A0AEC Q34987693-1FB76D2B-EAA0-4AE3-BFC2-141678763143 Q36129937-F14BCBDA-2114-495B-B281-954B1E051191 Q36290002-5BADEC29-51A7-49FE-BB1C-6E47487E61A1 Q36308766-50183E23-A1A9-4AD9-880A-A77C96568103 Q36502692-5C187B36-E697-40C1-B73C-1384BF1BF7AB Q36507013-2FCA9E44-6899-4AF5-9496-C3E6D5DBD811 Q37390670-2D02184C-342E-4196-8082-082E70B76E07 Q38172848-9408AFA0-BC02-407C-8066-FCE83715CF80 Q38190115-B925D25D-D3AF-4874-A764-34A602D88327 Q38211361-93A7D3C0-43A7-4448-AC6B-06364BD45FA3 Q38680652-3CD45F07-2105-4A6B-A279-2F8EE0DD40AB Q38746311-95F35B4C-E26C-48B5-AB09-A5E2D5E47290 Q38831029-8FE18CEB-E303-4FAD-9D03-B49A4B7506DB Q39003083-E294C11A-0295-4FAE-8839-538E891AFB61 Q40215364-0F48A5EB-4E80-4BAB-822B-85FCA14F21C9 Q42088489-9BA3D0FD-B8A1-492A-BF8A-3996D6090B8C Q42095619-A7A409C3-BF7F-4093-B61F-42C2A228E94F Q43119026-B29C290C-1DB6-449A-8C51-7844F0D5F0A7 Q44002717-35BF6C74-0F86-468C-B534-993393B40CEA Q47099005-841319EE-AC08-4FF0-B725-67206581369D Q47102678-70A3A8C1-BEC4-4012-87F6-5B142DD45D80 Q49713199-C291605F-4F6E-4A75-B3F7-5530B9007863 Q49919217-A3A055F0-2491-48DC-81FE-0B99533EE0E3 Q52982867-CB8CC2A4-03DA-4652-9780-9F9257F17A6E Q54536007-F46A1FDB-B366-4495-AB51-2272EDB9E6D8 Q55188040-F19D475D-CD38-4642-9564-AF730BDCDB10 Q58562169-628931AD-E91F-4620-8328-1188727ECBB4

P2860

Prospective evaluation of 18F-NaF and 18F-FDG PET/CT in detection of occult metastatic disease in biochemical recurrence of prostate cancer

http://www.wikidata.org/entity/Q36033412

description

2012 nî lūn-bûn

@nan

2012年の論文

@ja

2012年論文

@yue

2012年論文

@zh-hant

2012年論文

@zh-hk

2012年論文

@zh-mo

2012年論文

@zh-tw

2012年论文

@wuu

2012年论文

@zh

2012年论文

@zh-cn

name

Prospective evaluation of 18F- ...... recurrence of prostate cancer

@ast

Prospective evaluation of 18F- ...... recurrence of prostate cancer

@en

type

label

Prospective evaluation of 18F- ...... recurrence of prostate cancer

@ast

Prospective evaluation of 18F- ...... recurrence of prostate cancer

@en

prefLabel

Prospective evaluation of 18F- ...... recurrence of prostate cancer

@ast

Prospective evaluation of 18F- ...... recurrence of prostate cancer

@en

P1433

Q36033412-A655BF92-DC4F-45D4-98A8-241EE0CCC378

P1476

Q36033412-7D81EA2D-BC0E-4460-8C41-39C84EC8E4F4

P2093

Q36033412-0A2D2358-163A-4D5A-BB7B-6531DB56F998

Q36033412-2B9B720E-C620-4A88-A0E5-B0033C4613CE

Q36033412-36EEDA43-A794-4B51-8ED3-DC2CCF0F5BD7

Q36033412-437B04CD-D96B-4F77-9039-816E62FF40F0

Q36033412-AF851122-92EC-42B4-91C5-0ADCBA174D77

Q36033412-BC74C586-609C-42B2-91A4-57CD617C468C

Q36033412-DE6EBD09-63EE-41FA-8441-45C065E41129

P2860

Q36033412-1BAC16B7-8606-440C-B51E-B9C3757904E1

Q36033412-1BD92F7C-A9FF-43E7-993D-66B0E813F696

Q36033412-1E870948-A9FB-49AF-AF33-5CB99F89526F

Q36033412-2B80EC0A-075A-42D4-A5CA-BF3F8D9BB464

Q36033412-2C1CCFC5-E1B6-46F3-A95C-6B848355843A

Q36033412-34F28DC4-4DB1-495F-A1F6-F38B839A5717

Q36033412-42347CC6-E1E7-41C1-A9CC-32135B39C75D

Q36033412-6A383824-34E5-446F-BD0A-B60C5D241742

Q36033412-77ED42E2-EEC4-413D-8785-B550B373C846

Q36033412-7BBE0707-31A4-4569-A3D9-908620332FC2

P304

Q36033412-513E897F-0963-4AFA-8267-BBA187C70D49

P31

Q36033412-D3BCF44C-87D2-4DB5-A8D2-F17CF35D5AB4

P356

Q36033412-A4C10024-5521-4743-B18B-C7A60FF11B44

P433

Q36033412-A0796D34-4B68-4342-94D3-9EC625A65130

P478

Q36033412-AD503B22-6799-4557-87E8-EF7F6123BC48

P50

Q36033412-6AD5877E-0089-457F-8E73-C7E69A90D077

Q36033412-EF4890A7-37AD-4476-A00A-96A8CF3505D1

P577

Q36033412-6E922B6D-97F9-43C4-9A15-79C2A32FAF05

P698

Q36033412-9329CAB9-2BE5-4415-86B5-F839E47A7B52

P932

Q36033412-6191702A-7E45-44EA-A58D-64C30BF2FBCB

P356

RLU.0B013E318252D829

P1433

Clinical Nuclear Medicine

P1476

Prospective evaluation of 18F- ...... recurrence of prostate cancer

@en

P2093

Bhushan Desai

http://www.w3.org/2001/XMLSchema#string

Hossein Jadvar

http://www.w3.org/2001/XMLSchema#string

Jacek K Pinski

http://www.w3.org/2001/XMLSchema#string

Lingyun Ji

http://www.w3.org/2001/XMLSchema#string

Peter S Conti

http://www.w3.org/2001/XMLSchema#string

Susan G Groshen

http://www.w3.org/2001/XMLSchema#string

Tanya B Dorff

http://www.w3.org/2001/XMLSchema#string

P2860

Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group.

Capromab Pendetide imaging of prostate cancer.

Rising PSA after a radical treatment.

Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendations of the RTOG-ASTRO Phoenix Consensus Conference.

Causes and consequences of increased glucose metabolism of cancers.

Novel tracers and their development for the imaging of metastatic prostate cancer.

Molecular imaging of prostate cancer with 18F-fluorodeoxyglucose PET.

The role of choline positron emission tomography/computed tomography in the management of patients with prostate-specific antigen progression after radical treatment of prostate cancer.

Prostate cancer--biology of metastasis and its clinical implications.

Detecting metastatic pelvic lymph nodes by 18F-2-deoxyglucose positron emission tomography in patients with prostate-specific antigen relapse after treatment for localized prostate cancer.

P304

637-643

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1097/RLU.0B013E318252D829

http://www.w3.org/2001/XMLSchema#string

P433

7

http://www.w3.org/2001/XMLSchema#string

P478

37

http://www.w3.org/2001/XMLSchema#string

P50

P577

2012-07-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

22691503

http://www.w3.org/2001/XMLSchema#string

P932

3375600

http://www.w3.org/2001/XMLSchema#string